Cargando…
A genomic approach to predict synergistic combinations for breast cancer treatment
We leverage genomic and biochemical data to identify synergistic drug regimens for breast cancer. In order to study the mechanism of the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) in breast cancer, we generated and validated genomic profiles...
Autores principales: | Soldi, Raffaella, Cohen, Adam L, Cheng, Luis, Sun, Ying, Moos, Philip, Bild, Andrea H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450767/ https://www.ncbi.nlm.nih.gov/pubmed/22083351 http://dx.doi.org/10.1038/tpj.2011.48 |
Ejemplares similares
-
Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers
por: Cohen, Adam L, et al.
Publicado: (2013) -
A pharmacogenomic method for individualized prediction of drug sensitivity
por: Cohen, Adam L, et al.
Publicado: (2011) -
Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility
por: Piccolo, Stephen R., et al.
Publicado: (2015) -
ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
por: Nath, Aritro, et al.
Publicado: (2022) -
Prediction of Synergistic Antibiotic Combinations by Graph Learning
por: Lv, Ji, et al.
Publicado: (2022)